The present invention includes novel cyclic peptides, and methods of using the same. The present invention further includes novel cyclic peptides conjugated with a gold nanoparticle, and methods of using the same.
C07K 7/56 - Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation not occurring through 2,4-diamino-butanoic acid
A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
MXene-coated antennas, and associated devices and methods of manufacture, are described herein. In one aspect, an antenna may include an antenna body, where the antenna body has a coated region with a MXene film conformally coated thereon. The implementation of MXene-based waveguide components provides an example of a facile, convenient realization of 3D-printed polymer devices with performance levels as high as metallic waveguides. The waveguide and other conductive components can be additively manufactured using commonly available 3D printers and commercially available polymers. Dip-coating of MXene provides a general solution for realizing geometrically complex metal-like 3D structures. The disclosure provides herein the implementation of thru, bent, twisted, and discontinuous filtering waveguides, each of which can be utilized to manipulate the propagation of electromagnetic waves.
H01Q 19/10 - Combinations of primary active antenna elements and units with secondary devices, e.g. with quasi-optical devices, for giving the antenna a desired directional characteristic using reflecting surfaces
4.
DNA mapping and sequencing on linearized DNA molecules
The present invention provides novel methods for immobilizing and/or optically mapping oligonucleotides, the method comprising immobilizing the oligonucleotides on a micropatterned substrate. In another aspect, the invention provides a method for mapping a genome, wherein the method is capable of resolving a single nucleotide polymorphism (SNP), the method comprising introducing to the genome a CRISPR/Cas9 system comprising at least one single-guide RNA (sgRNA) specific for a target sequence or a plurality of target sequences across the genome and a Cas9 D10A, wherein the CRISPR/Cas9 system nick labels the target sequence, and the target sequence or genome is analyzed.
The present invention(s) is directed to novel conductive Mn+1Xn(Ts) compositions exhibiting high volumetric capacitances, and methods of making the same. The present invention(s) is also directed to novel conductive Mn+1Xn(Ts) compositions, methods of preparing transparent conductors using these materials, and products derived from these methods.
C04B 35/56 - Shaped ceramic products characterised by their compositionCeramic compositionsProcessing powders of inorganic compounds preparatory to the manufacturing of ceramic products based on non-oxides based on carbides
C04B 35/58 - Shaped ceramic products characterised by their compositionCeramic compositionsProcessing powders of inorganic compounds preparatory to the manufacturing of ceramic products based on non-oxides based on borides, nitrides or silicides
The present disclosure is directed to nanocomposites comprising a co-sintered composition of a MXene crystal form composition and an inorganic oxide, or oxide-type ceramic and methods of making and using the same.
C04B 35/56 - Shaped ceramic products characterised by their compositionCeramic compositionsProcessing powders of inorganic compounds preparatory to the manufacturing of ceramic products based on non-oxides based on carbides
C04B 35/453 - Shaped ceramic products characterised by their compositionCeramic compositionsProcessing powders of inorganic compounds preparatory to the manufacturing of ceramic products based on oxides based on zinc, tin or bismuth oxides or solid solutions thereof with other oxides, e.g. zincates, stannates or bismuthates
The invention relates to the compositions and methods for complete excision of HIV-1 proviral genomes including viral quasi-species (vQS) from an HIV-1-infected human. The invention includes a composition of guide RNAs (gRNAs) designed to specifically target the HIV-1 LTR region or any other region of the HIV-1 genome. The invention further includes a method for treating an HIV-1-infected human using the clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated (Cas) 9 system and the compositions of the present invention.
C12Q 1/70 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving virus or bacteriophage
C12Q 1/6809 - Methods for determination or identification of nucleic acids involving differential detection
C12Q 1/6876 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
C12Q 1/689 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
G01L 1/22 - Measuring force or stress, in general by measuring variations in ohmic resistance of solid materials or of electrically-conductive fluidsMeasuring force or stress, in general by making use of electrokinetic cells, i.e. liquid-containing cells wherein an electrical potential is produced or varied upon the application of stress using resistance strain gauges
D02G 3/44 - Yarns or threads characterised by the purpose for which they are designed
D06M 11/58 - Treating fibres, threads, yarns, fabrics or fibrous goods made from such materials, with inorganic substances or complexes thereofSuch treatment combined with mechanical treatment, e.g. mercerising with nitrogen or compounds thereof, e.g. with nitrides
D06M 11/74 - Treating fibres, threads, yarns, fabrics or fibrous goods made from such materials, with inorganic substances or complexes thereofSuch treatment combined with mechanical treatment, e.g. mercerising with carbon or compounds thereof with carbon or graphiteTreating fibres, threads, yarns, fabrics or fibrous goods made from such materials, with inorganic substances or complexes thereofSuch treatment combined with mechanical treatment, e.g. mercerising with carbon or compounds thereof with carbidesTreating fibres, threads, yarns, fabrics or fibrous goods made from such materials, with inorganic substances or complexes thereofSuch treatment combined with mechanical treatment, e.g. mercerising with carbon or compounds thereof with graphitic acids or their salts
G01L 19/00 - Details of, or accessories for, apparatus for measuring steady or quasi-steady pressure of a fluent medium insofar as such details or accessories are not special to particular types of pressure gauges
THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF AGRICULTURE (USA)
Inventor
Inman, Corey Alexander
Capobianco, Jr., Joseph A.
Gogotsi, Yury
Abstract
Herein we demonstrate a method of high energy delamination called high pressure homogenization (HPH) that combines high shear, cavitation forces, and impact forces to delaminate MXene without any post-process refinement steps or chemical intercalants. HPH-delaminated MXene can be made at scale with high throughput and yield with virtually no waste. We demonstrate the viability of this process by fabricating free-standing films with the material for use as electrodes for energy storage, and as an effective antimicrobial coating with a two-log reduction in pathogenic microbes.
Disclosed is a method for treating actinic keratosis of tissue of a patient, the method including contacting non-thermal, atmospheric pressure plasma over areas of the tissue having actinic keratosis for a time and at treatment conditions effective to give rise to an at least partial amelioration of the keratosis.
Described herein is a method of categorizing a cancer (such as into TEL+ cancer or ALT+ cancer). The method includes performing a global analysis of telomere lengths in cancer cells of the cancer, and determining the category of the cancer based on patterns of telomere lengths. Also described herein is a method of treating cancer based on the categorizing of the cancer.
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
C12Q 1/683 - Hybridisation assays for detection of mutation or polymorphism involving restriction enzymes, e.g. restriction fragment length polymorphism [RFLP]
abb wherein M is at least one element selected from the group consisting of Groups 3, 4, 5, 6, or 7, Q is at least one element (here, O is excluded) selected from the group consisting of Groups 12, 13, 14, 15, or 16, a is 0 or more and 2 or less, and b is more than 0 and 2 or less, wherein in a Raman spectrum, an average intensity at 745 to 765 cm-1is smaller than an average intensity at 735 to 745 cm-1, and wherein a pore volume is 0.060 cc/g or more.
A nondestructive evaluation method for determining the material used in a below-ground service line includes inserting a probe with a wave measurement device therein into an area corresponding to a location of a service line; generating a service line wave through an exposed portion of the service line using a vibratory shaker or other mechanical excitation; measuring, by the wave measurement device, a substrate wave created by the service line wave passing thought the service line and into the substrate; identifying, by a data acquisition system, the service line wave velocity and attenuation; comparing the service line wave velocity and attenuation to a known set of wave velocities and attenuations in service lines according to a service line material; and identifying the service line material in the service line by comparing the wave velocity and attenuation in the service line with the known set of wave velocities and attenuations.
The disclosure provides compounds of formula (II) having the structure:
The disclosure provides compounds of formula (II) having the structure:
The disclosure provides compounds of formula (II) having the structure:
Compounds of formula (II) are fractalkine receptor agonists and useful in treating, preventing or minimizing metastasis in a subject diagnosed with cancer. The compounds of the disclosure are further useful in treating central nervous system diseases (such as, but not limited to, HIV Associated Neurocognitive Disorders (HAND), and/or Alzheimer's disease), pain, inflammation (such as, but not limited to, arthritis), cardiovascular disease (such as, but not limited to, undesired vascular smooth muscle proliferation, atherosclerosis, coronary vascular endothelial dysfunction, and/or coronary artery disease), and/or multiple sclerosis.
A61K 31/337 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
A61K 31/704 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin, digitoxin
C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or
16.
COMPOSITIONS AND METHODS FOR MACROPHAGE CONVERSION
One aspect of the invention provides a method of treating a chronic wound including administering to the wound at least one agent from a delivery system wherein the agent induces sequential conversion of a first population of wound macrophages in the wound to M2A macrophages and a second population of wound macrophages to M2C macrophages. The sequential conversion of the wound macrophages promotes tissue remodeling.
A wireless charging station installed on the seafloor is equipped with multiple wireless transmitter coils and powered by a large-capacity lithium-battery-based energy storage system (ESS). Correspondingly, small-size wireless receiver coils are installed inside underwater robots and vehicles. When the battery is low in the underwater devices, the robots and vehicles automatically swim to the charging station and land in a specific charging region. After identifying the robots and vehicles, the wireless charging station can automatically start a wireless charging operation.
H02J 50/12 - Circuit arrangements or systems for wireless supply or distribution of electric power using inductive coupling of the resonant type
B60L 53/126 - Methods for pairing a vehicle and a charging station, e.g. establishing a one-to-one relation between a wireless power transmitter and a wireless power receiver
18.
TUNEABLE MXENE-BASED LENS DESIGN FOR SPECIFIC WAVELENGTH FILTRATION TO AID OCULAR DISORDERS AND PROTECT FROM POTENTIAL HARMFUL RADIATION
Provided are ophthalmic components (e.g., eyeglass lenses and contact lenses) that include a two dimensional crystalline solid material dispersed in a matrix material. The disclosed components can selectively filter light of selected wavelengths, thereby making the components suitable for use by individuals who may suffer from color vision deficiency conditions. The two dimensional crystalline solid material comprises at least one layer comprising a substantially two-dimensional array of crystal cells; each crystal cell having an empirical formula of M(n+1)X(n), such that each X is positioned within an array of M, wherein M is at least one Group IIIB, IVB, VB, VIB or VIIB metal, and wherein X is C and/or N.
G02B 1/04 - Optical elements characterised by the material of which they are madeOptical coatings for optical elements made of organic materials, e.g. plastics
An antimicrobial amphiphilic copolymer comprising units derived from one or more hydrophobic polymers and one or more hydrophilic polymers, wherein the copolymer is selected from the group consisting of non-ionic and anionic copolymers and the copolymer is a random copolymer or a block copolymer, methods for making the copolymer, coatings made from the copolymer and medical devices coated with the copolymer.
C08F 299/02 - Macromolecular compounds obtained by interreacting polymers involving only carbon-to-carbon unsaturated bond reactions, in the absence of non-macromolecular monomers from unsaturated polycondensates
ab b wherein M is at least one element selected from the group consisting of Groups 3, 4, 5, 6, or 7, Q is at least one element (here, O is excluded) selected from the group consisting of Groups 12, 13, 14, 15, or 16, a is 0 or more and 2 or less, and b is more than 0 and 2 or less.
B01J 20/06 - Solid sorbent compositions or filter aid compositionsSorbents for chromatographyProcesses for preparing, regenerating or reactivating thereof comprising inorganic material comprising oxides or hydroxides of metals not provided for in group
B01D 53/02 - Separation of gases or vapoursRecovering vapours of volatile solvents from gasesChemical or biological purification of waste gases, e.g. engine exhaust gases, smoke, fumes, flue gases or aerosols by adsorption, e.g. preparative gas chromatography
B82Y 30/00 - Nanotechnology for materials or surface science, e.g. nanocomposites
21.
Directable Tunnel Device for Subcutaneous Implantable Cardio Defibrillator
A directional tunnel device for a subcutaneous implantable device is provided. The tunnel device includes an elongate outer sleeve having an open proximal end and an open distal end. An elongate outer trough has a trough proximal end, a trough distal end, and a concave cradle extending between the trough proximal end and the trough distal end. The outer trough is sized to slidingly fit inside outer sleeve such that the outer sleeve is slidable externally along the outer trough. An inner glide rests in the cradle. The inner glide includes an inner trough, a guide arm connected to a distal end of the inner trough, and a pivot arm connected to a distal end of the guide arm.
An electrolyte solvent having a dielectric constant of 10 or less comprising: a) 0% to 30% by volume of one or more of components i)-iii), based on a total volume of the electrolyte solvent: i) one or more unsubstituted cyclic carbonate(s): ii) one or more unsubstituted lactone(s); and iii) one or more unsubstituted oxazolidine(s); and b) 70% to 100% by volume of one or more of components iv)-vii), based on the total volume of the electrolyte solvent: iv) one or more substituted cyclic carbonate(s) having 3-15 carbon atoms: v) one or more substituted lactone(s) having 3-15 carbon atoms; and vi) one or more substituted oxazolidine(s) having 3-15 carbon atoms; and vii) one or more acyclic carbonate(s) having 2-20 carbon atoms. A method of making a cathode and cathodes and batteries made by the methods are also disclosed.
The present disclosure relates, in one aspect, to hydrogel compositions comprising a nanoparticle, functionalized polymer, and a therapeutic agent. In certain embodiments, the hydrogel compositions of the disclosure are suitable for local delivery of a therapeutic agent.
A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
Korea Institute of Science and Technology (Republic of Korea)
Inventor
Gogotsi, Yury
Anasori, Babak
Alhabeb, Mohamed H.
Hatter, Christine B.
Koo, Chong Min
Hong, Soon Man
Shahzad, Faisal
Abstract
The present disclosure is directed to materials which provide electromagnetic shielding and methods of providing such electromagnetic shielding. In particular, the present disclosure describes the use of two-dimensional transition metal carbide, nitride, and carbonitride materials for this purpose.
Reconfigurable intelligent surfaces (RISs) are an emerging transmission technology to aid wireless communication. However, the potential of using RIS to mitigate directed energy weapons (DEW) is not widely recognized. Described herein are RIS (based on spiral antenna elements) to aid the mitigation of high-energy radio-frequency (RF) sources applied to a DEW. For example, integrating a broadband circularly-polarized antenna system with RIS technology can successfully mitigate DEW attacks across a wide range of frequencies regardless of how radio waves are polarized. A spiral antenna is simulated that operates between 1.3 GHz and 7 GHz with a 3-dB axial ratio bandwidth (ARBW) covering 2 GHz-7 GHz. Full-wave simulation results show the potential promising application of RIS for the mitigation of DEW attacks.
H01Q 5/25 - Ultra-wideband [UWB] systems, e.g. multiple resonance systemsPulse systems
H04B 7/04 - Diversity systemsMulti-antenna systems, i.e. transmission or reception using multiple antennas using two or more spaced independent antennas
26.
FAULT CURRENT BYPASS BASED SOLID STATE CIRCUIT BREAKERS AND ACTIVE CLAMPING SNUBBERS FOR DC CIRCUIT BREAKERS
Solid-state circuit breakers (SSCBs) have been witnessing an impressive progress with the aid of wide bandgap (WBG) devices such as silicon carbide (SiC) MOSFETs. Along with obtaining high efficiency as the result of low on-state resistance, response times have been gaining remarkable achievements in microseconds range. Not only that, the reported successes in control and gate drivers design and incorporating fault detection/location techniques in SSCBs are promising. A MOV-resistive capacitive switch (MOV-RCS) snubber for solid state circuit breakers addresses the following: 1) the MOV degradation issue in DCCBs is solved, 2) the maximum allowable DC bus voltage on DCCBs is extended. The solid state circuit breaker and an active clamping snubber includes a first circuit including a fault current bypass based solid state breaker for low voltage direct current systems.
H03K 17/0812 - Modifications for protecting switching circuit against overcurrent or overvoltage without feedback from the output circuit to the control circuit by measures taken in the control circuit
H02H 3/087 - Emergency protective circuit arrangements for automatic disconnection directly responsive to an undesired change from normal electric working condition, with or without subsequent reconnection responsive to excess current for DC applications
27.
METHODS AND COMPOSITIONS FOR DREADD-ACTIVATABLE CELLS FOR NEURAL REPAIR
Provided herein are methods of training a machine-learning model to detect a neurological condition. The methods include providing a neurological condition dataset comprising neurological condition text embeddings, the neurological condition text embeddings including large language model (LLM) text embeddings from subjects having the neurological condition; providing a control dataset comprising control text embeddings, the control text embeddings including LLM text embeddings from healthy subjects; and training the machine-learning model using the neurological condition dataset and the control dataset, forming a trained machine-learning model configured to detect a neurological condition. Also provided herein are methods of detecting a neurological condition using the trained machine-learning model.
Disclosed herein are thin films and methods of forming thin films. An example thin film may comprise Ba—Ti—O configured to exhibit a structure where a distance of one or more neighboring Ti—Ti atoms is less than 3 Å.
H01G 7/06 - Capacitors in which the capacitance is varied by non-mechanical meansProcesses of their manufacture having a dielectric selected for the variation of its permitivity with applied voltage, i.e. ferroelectric capacitors
31.
ARTIFICIAL INTELLIGENCE ASSISTED COMPUTATIONAL FRAGMENT-BASED DRUG DESIGN
Provided herein are methods for improving drug discovery using artificial intelligence to identify compounds that are expected to have potent binding affinities at therapeutic targets of interest.
G06F 30/20 - Design optimisation, verification or simulation
G06F 18/2113 - Selection of the most significant subset of features by ranking or filtering the set of features, e.g. using a measure of variance or of feature cross-correlation
G06F 18/2115 - Selection of the most significant subset of features by evaluating different subsets according to an optimisation criterion, e.g. class separability, forward selection or backward elimination
G06F 18/2132 - Feature extraction, e.g. by transforming the feature spaceSummarisationMappings, e.g. subspace methods based on discrimination criteria, e.g. discriminant analysis
A material, comprising: a coherent structure comprising a plurality of entangled titania filaments having a lepidocrocite crystal structure. A method, comprising: with a suspension comprising (1) a plurality of titania filaments having a lepidocrocite crystal structure and (2) a solvent, effecting at least partial removal of the solvent so as to give rise to a material according to the present disclosure. A composition, comprising: a plurality of titania filaments having a lepidocrocite crystal structure; and a solvent, the plurality of titania filaments being suspended in the solvent.
Processes of producing nanoparticles from solid phase precursor non-nanoparticles. Contacting a solid phase precursor non-nanoparticle selected from oxides of metals and metalloids, carbides of metals and metalloids, nitrides of metals and metalloids, borides of metals and metalloids, silicides of metals and metalloids, and phosphides of metals and metalloids, and mixtures thereof, with one or more onium ions in water in a vessel. Some processes can be one pot processes. The vessel is agitated and held at temperature for a time sufficient to form nanoparticles with the same crystalline structure as the solid phase precursor non-nanoparticle as determined by XRD and/or TEM. Nanoparticles made by the processes. Processes of use of the nanoparticles.
Described herein is a method of diagnosing Lyme disease in a subject. The method includes determining a glycosylation profile of a protein whose glycosylation profile is associated with Lyme disease in a subject, and comparing the glycosylation profile of the protein with a predetermined glycosylation profile of the protein indicating free of Lyme disease or a predetermined glycosylation profile of the protein indicating Lyme disease. Further described herein is a method of treating and/or ameliorating Lyme disease in a subject. The method includes diagnosing Lyme disease in a subject and, if the subject is diagnosed to have Lyme disease, administering to the subject an effective amount of compound effective for treating Lyme disease. Further described herein is a method of evaluating a treatment for Lyme disease. The method includes comparing a glycosylation profile of the patient with glycosylation profiles associated with successful/unsuccessful treatments.
G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
A61K 31/431 - Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula , e.g. penicillins, penems containing further heterocyclic ring systems, e.g. ticarcillin, azlocillin, oxacillin
A61K 31/7036 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
35.
MULTI COLOR WHOLE-GENOME MAPPING AND SEQUENCING IN NANOCHANNEL FOR GENETIC ANALYSIS
In one aspect, the invention provides universal multi-color mapping strategy in nanochannels combining conventional sequence-motif labeling system with Cas9 mediated target-specific labeling of any 20-base sequences (20mers) to create custom labels and detect new features. The sequence-motifs are labeled with green fluorophores and the 20mers are labeled with red fluorophores. Using this strategy, it is not only possible to detect the (structural variants) SVs but it is also possible to utilize custom labels to interrogate the features not accessible to motif-labeling, locate breakpoints and precisely estimate copy numbers of genomic repeats. In another aspect, the invention provides CRISPR-Cas9 enabled whole-genome sequencing.
A two-dimensional particle including: one or plural layers, the one or plural layers having a layer body represented by: MmXn, wherein M is at least one metal of Group 3, 4, 5, 6, or 7, X is a carbon atom, a nitrogen atom, or a combination thereof, n is 1 to 4, m is more than n but not more than 5, and a modifier or terminal T existing on a surface of the layer body, wherein T is at least one selected from a hydroxyl group, an amine group, a fluorine atom, a chlorine atom, a bromine atom, an iodine atom, an oxygen atom, a sulfur atom, a selenium atom, a tellurium atom and a hydrogen atom; a metal cation is at least one cation selected from Na and K, and a content of Li in the two-dimensional particle is less than 0.002% by mass.
C01B 32/907 - OxycarbidesSulfocarbidesMixture of carbides
A61B 5/263 - Bioelectric electrodes therefor characterised by the electrode materials
B01J 20/02 - Solid sorbent compositions or filter aid compositionsSorbents for chromatographyProcesses for preparing, regenerating or reactivating thereof comprising inorganic material
B01J 20/28 - Solid sorbent compositions or filter aid compositionsSorbents for chromatographyProcesses for preparing, regenerating or reactivating thereof characterised by their form or physical properties
B01J 20/30 - Processes for preparing, regenerating or reactivating
C08K 9/02 - Ingredients treated with inorganic substances
By combining two-dimensional (2D) transition metal oxide and/or carbo-oxides with sulfur, one can form cathodes for use in Li—S batteries, which batteries in turn exhibit high capacity and other attractive characteristics. Accordingly, provided herein are methods, comprising: forming an admixture that comprises sulfur, a 2D transition metal carbo-oxide, and optionally a conductive material. Also provided are electrodes, comprising sulfur, a 2D transition metal carbo-oxide, and optionally a conductive material. Further provided are energy cells, the energy cell comprising a first electrode according to the present disclosure. Additionally provided are methods, the methods comprising discharging an energy cell according to the present disclosure or charging an energy cell according to the present disclosure. Also provided are electrical devices, comprising an energy cell according to the present disclosure.
The disclosure provides a human-safe method of killing or controlling insects using a non-toxic composition comprising erythritol ((2R,3S)-butane-1,2,3,4-tetraol). The disclosure also provides non-toxic compositions comprising erythritol suitable for killing insects in residential, commercial, and agricultural locales.
A01N 25/00 - Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of applicationSubstances for reducing the noxious effect of the active ingredients to organisms other than pests
A01N 25/30 - Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of applicationSubstances for reducing the noxious effect of the active ingredients to organisms other than pests characterised by the surfactants
In absence of electrical approaches for realization of highly stable RF oscillator, opto-electronic oscillators (OEO) techniques are provided, where self-forced oscillation techniques using long optical delays demonstrate significant short-term and long-term frequency stability. Fully integrated opto-electronic oscillator chip (IOEC) may be the most efficient realization of an RF frequency synthesizer in terms of operation frequency (covering microwave and millimeter wave), size (<10 cm3), ruggedness to environmental effects of temperature (−40 to 80C), vibration (up to 40g), low timing jitter (<5fs for 40 GHz carrier), and wall-plug efficiency (output power >10 dBm from under 1 W power). A free-running III-V (primarily InP) based multi-mode laser (MML) diodes is designed with large mode number (e.g., over 60 modes) and intermodal oscillation frequency compatible with desired RF carrier signal (e.g., 1-40 GHz).
Government of USA, by The Secretary of the Army (USA)
Inventor
Palmese, Giuseppe R.
Kinaci, Emre
Lascala, John J.
Abstract
A polymerizable monomer prepared by reacting at least one epoxidized cardanol with (meth)acrylic anhydride or (meth)acryloyl chloride in the presence of one or more of triethylamine, tertiary amines, pyridines and pyridine derivatives; wherein the epoxidized cardanol is formed by epoxidation of an unsaturation site of a cardanol having the formula (I): wherein R is selected from hydrogen and an alkyl, or alkenyl group having 1-6 carbon atoms, and n is 7, 10, or 13, a polymer and resin made form the polymerizable monomer, and a method of preparing such a polymer. The resin created from this monomer is suitable for moderate temperature composites and coatings applications.
C07C 39/19 - Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring monocyclic with unsaturation outside the aromatic ring containing carbon-to-carbon double bonds but no carbon-to-carbon triple bonds
C08F 222/20 - Esters containing oxygen in addition to the carboxy oxygen
41.
METHODS OF IDENTIFYING AND TREATING TUMORS WITH SIGMA1 INHIBITORS
Methods and uses of using Sigma1 inhibitors are provide herein, including diagnostic methods for predicting or identifying quantitatively whether a human tumor is responsive or non-responsive to treatment with Sigma1 inhibition are also provided.
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
A61K 31/4745 - QuinolinesIsoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenanthrolines
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
G16B 40/10 - Signal processing, e.g. from mass spectrometry [MS] or from PCR
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
42.
WEARABLE AND PORTABLE SMART ACTUATION DEVICE FOR DVT RISK MITIGATION: DEEP VEIN THROMBOSIS PREVENTION DEVICE (DVT-PD)
A deep vein thrombosis prevention device (DVT-PD) is a wearable device for the lower extremities senses the user's dynamic or static movements and actuates accordingly to lower DVT risks. The device uses a comprehensive control system together with an integrated machine learning model. to classify, manage, direct, and regulate signals and the behavior of the device.
A61N 1/36 - Applying electric currents by contact electrodes alternating or intermittent currents for stimulation, e.g. heart pace-makers
G16H 40/63 - ICT specially adapted for the management or administration of healthcare resources or facilitiesICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for local operation
43.
Dendrite-Free, Wide Temperature Range Lithium Metal Batteries Enabled by Hybrid Network Ionic Liquids
Ionic liquid N-methyl-N-propyl-pyrrolidinium bis(fluorosulfonyl)imide (Pyr13FSI) was introduced into a hybrid network to obtain a series of gel polymer electrolytes (GPEs). Mechanical and electrochemical properties of the GPEs were tuned through controlling the network structure and ionic liquid contents, and ionic conductivity higher than 1 mS cm−1 at room temperature was achieved. The newly developed GPEs are flame-retardant and show excellent thermal and electrochemical stability as well as ultra-stability with lithium metal anode. Symmetrical lithium cells with the GPEs exhibit a stable cycling over 6800 h at a current density of 0.1 mA cm−2 and stable lithium stripping-plating at 1 mA cm−2, the highest current density reported for ionic liquid-based GPEs. Moreover, Li/LiFePO4 batteries with the obtained GPEs exhibit desirable cycling stability and rate performance over a wide temperature range from 0° C. to 90° C.
A key-based interleaver for enhancement the security of wireless communication includes a physical layer communication channel key to provide security even when the software encryption key is compromised. A method of creating a secure communication link using a physical layer interleaving system includes implementing a key policy implementation that utilizes temporal dependency and interleaving bits using a flexible inter and intra-block data interleaver.
The present invention includes novel RAD52 inhibitors for preventing or treating cancers in a subject in need thereof. The present invention further includes a method of preventing or treating cancers in a subject in need thereof, the method comprising administering to the subject an effective amount of a compound of the invention. In certain embodiments, the subject is further administered at least one additional therapeutic agent.
A61K 31/4188 - 1,3-Diazoles condensed with heterocyclic ring systems, e.g. biotin, sorbinil
A61K 31/4525 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
A61K 31/4741 - QuinolinesIsoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
A61K 31/517 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
A61K 31/55 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
C07D 239/95 - QuinazolinesHydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
C07D 307/82 - Benzo [b] furansHydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
C07D 405/12 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 491/048 - Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
C07D 491/056 - Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
46.
Multifunctional Nanoparticles For Prevention And Treatment Of Atherosclerosis
A61K 47/14 - Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
A61K 47/20 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
A61K 47/24 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
A61K 47/32 - Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers
A61K 47/36 - PolysaccharidesDerivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
A61K 47/42 - ProteinsPolypeptidesDegradation products thereofDerivatives thereof, e.g. albumin, gelatin or zein
A61K 47/44 - Oils, fats or waxes according to two or more groups of Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
47.
Use Of Cold Atmospheric Pressure Plasma To Treat Warts
A method for treating a wart on skin of a patient includes guiding non-thermal, atmospheric pressure plasma over areas of the tissue having the wart for a length of time effective to give rise to an at least partial amelioration of the wart.
Methods of making a cathode active material, including steps of: a) mixing a conductive polymer, a nitrogen containing polymer or a combination of a conductive polymer and a nitrogen-containing polymer with sulfur in the presence of a solvent to form a mixture, using a weight ratio of the conductive polymer and/or nitrogen containing polymer to the sulfur of from about 1:2 to about 1:8; and b) heating the mixture to a temperature of from about 250#C to about 400#C under a pressure of from about 0.05 bar to about 2.0 bar to form the cathode active material. A cathode active material formed by the method and cells and batteries employing the cathode active material.
Described herein is method of treating and/or ameliorating a wound in a subject in need thereof. The method includes measuring an expression of a first and second panel of genes from a sample from the wound, wherein when at least one gene from the first panel is expressed, a pro-inflammatory agent is administed to the subject, and wherien when at least one gene from the second panel is expressed, an anti-inflammatory or M2 macrophage-promoting agent is administered to the subject, thus treating and/or ameliorating the wound in the subject.
C12Q 1/6809 - Methods for determination or identification of nucleic acids involving differential detection
G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indicesICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
A61P 17/02 - Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (USA)
DREXEL UNIVERSITY (USA)
Inventor
Watson, Amanda
Kendell, Claire
Lee, Insup
Weimer, James
Abstract
Methods and devices for advanced spectroscopy are described herein. In one aspect, a method for determining levels of a biomarker of a user by a mobile device can include: generating a first light having a first wavelength; collecting emission signals resulting from the first light interacting with the user; measuring emission counts of the emission signals over a period of time; causing to be determined at least one of (i) a level of the biomarker of the user and (ii) a change in the levels of the biomarker of the user over the period of time based on the measured emission counts; and generating a notification indicative of the at least one of (i) a level of the biomarker of the user and (ii) a change in the levels of the biomarker of the user.
A61B 5/145 - Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
51.
TUMOR BED IMPLANT FOR MULTIMODALITY TREATMENT OF AT RISK TISSUE SURROUNDING A RESECTION CAVITY
A device having a biocompatible polymer as a body and regularly spaced radiation seeds and regularly spaced magnetic materials disposed of within the body of the biocompatible polymer, or uniformly distributed liquid radiation and magnetic fluid materials within a polymer slab, hollow thick wall polymer shell, or thin wall polymer balloon, as suitable for surgical placement within a resection cavity for treatment of at-risk tissue in the tumor margin with local hyperthermia in combination with radiation and potentially also with chemotherapy and/or immunotherapy that is slowly released from the biocompatible polymer.
A61B 5/06 - Devices, other than using radiation, for detecting or locating foreign bodies
A61K 41/00 - Medicinal preparations obtained by treating materials with wave energy or particle radiation
A61K 51/12 - Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes
THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (USA)
SINAI HEALTH SYSTEM (Canada)
DREXEL UNIVERSITY (USA)
THE WISTAR INSTITUTE (USA)
UNIVERSITY OF LEEDS (United Kingdom)
Inventor
Greenberg, Roger
Sicheri, Frank
Zeqiraj, Elton
Salvino, Joseph M.
Abstract
The present disclosure provides for techniques using BRISC deubiquitinating enzyme inhibitors of formula (I) for treating and/ or preventing systemic lupus erythematosus (SLE). Accordingly, the present disclosure provides for compositions and methods for treating or preventing a disease or disorder mediated by inhibition of type I interferon receptor (IFNAR1) signaling.
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
A61P 37/06 - Immunosuppressants, e.g. drugs for graft rejection
C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
A61K 31/4155 - 1,2-Diazoles not condensed and containing further heterocyclic rings
C07D 403/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
C07D 409/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
An emergency C-Section task trainer includes a rigid frame, a simulated torso having an abdomen area mounted within the frame, and a simulated uterus in the torso below the abdomen area. A simulated fetus is located in the uterus. A plurality of first fluid conduits extends across the abdomen area and a plurality of second fluid conduits extends across the uterus.
A system develops classifiers that can aid medical professionals by diagnosing whether or not a patient has a medical condition like pneumothorax. The system breaks the task into multiple steps, using Y0L0v4 to extract relevant regions of the video and a 3D sparse coding model to represent video features. Given the difficulty in acquiring positive training videos, the inventors trained a small-data classifier with a maximum of 15 positive and 32 negative examples. To counteract this limitation, the inventors leveraged subject matter expert (SME) knowledge to limit the hypothesis space, thus reducing the cost of data collection. The inventors present results using two lung ultrasound datasets and demonstrate that the inventors' model is capable of achieving performance on par with SMEs in pneumothorax identification.
G06V 10/764 - Arrangements for image or video recognition or understanding using pattern recognition or machine learning using classification, e.g. of video objects
G06V 10/82 - Arrangements for image or video recognition or understanding using pattern recognition or machine learning using neural networks
A61B 8/00 - Diagnosis using ultrasonic, sonic or infrasonic waves
G16H 30/20 - ICT specially adapted for the handling or processing of medical images for handling medical images, e.g. DICOM, HL7 or PACS
G16H 30/40 - ICT specially adapted for the handling or processing of medical images for processing medical images, e.g. editing
55.
SYSTEM TO DEFEND AGAINST PUPPETEERING ATTACKS IN AI-BASED LOW BANDWIDTH VIDEO
A system defends against puppeteering attacks in low bandwidth talking head videoconferencing systems. The defensive system is a software that can be embedded within existing platforms or an operating system and it exploits the fact that the facial expression and pose information sent to the receiver inherently contain biometric information about the driving speaker. The system leverages this information to obtain measurements of the biometric distance between the driving and reconstructed speaker. If the biometric distance becomes large, this indicates that the driving speaker is a different person than the reconstructed speaker. The system then flags the video transmission as a puppeteering attack.
G06V 40/40 - Spoof detection, e.g. liveness detection
G06V 10/764 - Arrangements for image or video recognition or understanding using pattern recognition or machine learning using classification, e.g. of video objects
A dynamic capacitive power transfer system for an elevator that can realize the real-time powering of the elevator when it is in the moving status. It includes a metal track along the building side as the power transmitter and a piece of metal at the elevator side as the power receiver. There is a gap between the transmitter and receiver, and up to kW power can be transferred wirelessly and efficiently to serve the air conditioner, lightning, and other electronic devices in the moving car. The steel wheels and ropes may be used to connect the moving car to the earth ground, which contributes to form the current returning loop. It eliminates the electric cables and the corresponding flexible cable carrier system for the linear movement.
Described herein is a method of treating, ameliorating, and/or preventing post-operative pain in a subject using certain compositions recited in the disclosure. The method comprises administering to the subject a therapeutically effective of a composition comprising a small extracellular vesicle (sEV) or an exosome released by a macrophage. Also described herein is a method of performing surgical operation. The method comprises performing a surgery on the subject, as well as administering to the subject the composition comprising the sEV or exosome herein.
A61K 35/15 - Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cellsMyeloid precursor cellsAntigen-presenting cells, e.g. dendritic cells
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61P 25/04 - Centrally acting analgesics, e.g. opioids
Provided are methods for etching MAX-phase materials to produce MXenes, the etching being accomplished by a salt, one or both of a polar and a non-polar solvent, and optionally a crown ether, the etching also being optionally performed in a water-free or essentially water-free manner. Also provided are related systems and methods.
B01J 4/00 - Feed devicesFeed or outlet control devices
B01J 8/02 - Chemical or physical processes in general, conducted in the presence of fluids and solid particlesApparatus for such processes with stationary particles, e.g. in fixed beds
59.
COMPOSITIONS AND METHODS FOR TREATING A DISORDER OR DEFECT IN SOFT TISSUE
The present invention encompasses methods and compositions for generating a biomimetic proteoglycan. The invention includes methods of treating a disease, disorder, or condition of soft tissue using a biomimetic proteoglycan.
Backpropagation enabled neural network optimization, but is still expensive at scale. An efficient alternative for neural networks must reduce scaling costs and provide high-efficiency optimizations. The presented solution for feed-forward layers is extended compositionally, for transformers containing feed-forward and self-attention layers. These train complex models modularized by self-attentive feed-forward units (SAFFUs), defining efficient architectures that generalize over much less data. Results demonstrate outperformance of backpropagation (alone), compared to application of backpropagation after explicit solutions, which uncover better optima from less data. Ablations train a roadmap of 245 transformers to determine specifications for the SAFFU- transformer, showing several architectural variants appear quite performant. The most performant models appear to not be the most parameterized. Summarizing, well-generalized SAFFU models are efficiently reachable, their architectural explorability via explicit solutions is cheaper and more robust than by backpropagation, and their explicit solutions could be useful for low-resource hardware, where Al might be embodied.
Described herein is a method of diagnosing Lyme disease in a subject. The method includes determining a glycosylation profile of a protein whose glycosylation profile is associated with Lyme disease in a subject, and comparing the glycosylation profile of the protein with a predetermined glycosylation profile of the protein indicating free of Lyme disease or a predetermined glycosylation profile of the protein indicating Lyme disease. Further described herein is a method of treating and/or ameliorating Lyme disease in a subject. The method includes diagnosing Lyme disease in a subject and, if the subject is diagnosed to have Lyme disease, administering to the subject an effective amount of compound effective for treating Lyme disease.
G01N 27/26 - Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating electrochemical variablesInvestigating or analysing materials by the use of electric, electrochemical, or magnetic means by using electrolysis or electrophoresis
An integrated portable extremely fast charger (XFC) may be installed for heavy-duty off-road vehicles, such as tractors and combine harvesters. The XFC shortens the charging period of plug-in hybrid electric vehicles (PHEVs) and battery electric vehicles (BEVs) by providing >500 kW in a single charger. The proposed XFC integrates a solar farm and local energy storage system (ESS) such that the local grid only needs to provide the power gap between the vehicle battery and the local ESS during charging events, yielding a low-cost XFC installation and higher renewable energy penetration. Two design approaches for the XFC, conductive and wireless, are based on multiphase interleaved dc-dc converter circuit, permitting flexible access to electricity. Smart fault protection mechanism is also proposed to achieve high safety during charging events. The hexagonal prism charger may be integrated into the power electronic devices with a transformer, yielding a high compactness and power density.
The United States of America as represented by The Secretary of the Army (USA)
Inventor
Palmese, Giuseppe R.
Yadav, Santosh K.
Lascala, John J.
Abstract
Benzoxazine compounds, methods of making them, polymers made therefrom and methods of polymerizing the benzoxazines. These renewable benzoxazine monomers and polymers that utilize the variety of building blocks found in renewable plant biomass, demonstrate excellent processability and large temperature windows for processing of resin systems.
C07D 413/06 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
C07D 307/52 - Radicals substituted by nitrogen atoms not forming part of a nitro radical
C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Provided are methods to convert—through a bottom-up approach—binary and ternary titanium carbides, nitrides, borides, phosphides, aluminides, and silicides into lepidocrocitic nanofilaments that in some cases self-assemble into 2D flakes by immersing them in a quaternary ammonium solution at moderate temperatures. The resulting flakes can comprise nanofilaments in cross-section, some of which nanofilaments can be few microns long in some instances.
H01M 4/1397 - Processes of manufacture of electrodes based on inorganic compounds other than oxides or hydroxides, e.g. sulfides, selenides, tellurides, halogenides or LiCoFy
H01M 4/136 - Electrodes based on inorganic compounds other than oxides or hydroxides, e.g. sulfides, selenides, tellurides, halogenides or LiCoFy
65.
DYEING METHOD FOR COLORATION OF ULTRA-HIGH MOLECULAR WEIGHT POLYETHYLENE FIBER
A method or coloring a ultra-high molecular weight polyethylene (UHMWPE) fiber includes the steps of: gel spinning the UHMWPE fiber, the fiber having an amorphous content of about 30% to about 60%; winding the fiber on a perforated spool for dyeing; placing the spool-wound fiber into a super critical CO2 (scCO2) dyeing vessel; infusing a dye in the scCO2 into the spool-wound fiber; removing the spool-wound fiber from the dyeing vessel; unwinding the fiber from the spool; and hot drawing the fiber by a predetermined draw ratio to obtain a desired tensile strength and modulus for the fiber.
D01F 6/44 - Monocomponent man-made filaments or the like of synthetic polymersManufacture thereof from mixtures of polymers obtained by reactions only involving carbon-to-carbon unsaturated bonds as major constituent with other polymers or low-molecular-weight compounds
D01F 6/46 - Monocomponent man-made filaments or the like of synthetic polymersManufacture thereof from mixtures of polymers obtained by reactions only involving carbon-to-carbon unsaturated bonds as major constituent with other polymers or low-molecular-weight compounds of polyolefins
The present invention provides methods for preparing acoustically-sensitive microbubbles. The method includes the steps of providing a first system comprising at least one water-soluble surfactant; providing a second system comprising at least one water-insoluble surfactant, wherein providing the second system optionally comprises the step of autoclaving the second system and optionally cooling the resulting autoclaved system; and contacting the first system with the second system at the temperature below the melting point of the second surfactant, so as to produce a mixture comprising microbubbles.
The present disclosure is directed to antennas for transmitting and/or receiving electrical signals comprising a MXene composition, devices comprising these antennas, and methods of transmitting and receiving signals using these antennas.
Methods that include tagging at least one cell with a MXene, the cell optionally being an immune cell; and detecting at least one component of the MXene using one or more of single-cell mass cytometry by time-of-flight (CyTOF), imaging mass cytometry (IMC), and ion beam imaging (MIBI-TOF). Systems that include a cell tagged with an amount of a MXene; and a detection train configured for at least one of time of flight (CyTOF), imaging mass cytometry (IMC), and ion beam imaging by time-of-flight (MIBI-TOF) that detects the MXene. Methods that include tagging a population of cells with at least one MXene; and processing the population of cells with at least one of time-of-flight (CyTOF), imaging mass cytometry (IMC), and ion beam imaging by time-of-flight (MIBI-TOF) that detects the at least MXene; and relating the detection of the at least one MXene to a characteristic of the population of cells.
The present invention provides a method of treating or preventing an attention and/or cognitive disorder in a subject in need thereof, comprising administering to the subject a compound useful within the invention. The present invention further provides a method of treating or preventing dementia associated with a neurodegenerative disorder in a subject in need thereof, comprising administering to the subject a compound useful within the invention.
The present invention provides a method of treating or preventing an attention and/or cognitive disorder in a subject in need thereof, comprising administering to the subject a compound useful within the invention. The present invention further provides a method of treating or preventing dementia associated with a neurodegenerative disorder in a subject in need thereof, comprising administering to the subject a compound useful within the invention.
Vascularization in nature creates a constituent system that enhances thermal exchange between components and autonomously responds to different environmental stimuli, such as moisture and temperature, to create equilibrium for organisms. Infrastructure designed with traditional design methods often encounters degradation over their lifespan without featuring autonomous responses to chemical/mechanical deterioration imposed by harsh environments. Vascular architectures can be engineered for further application in construction materials to provide necessary mass/heat transport for thermo-regulation in infrastructure. This concept is investigated using a phase change material (PCM) liquid injected into various architected vascular networks. The invention provides vascular networks using sacrificial components at multi-length scales and integrates PCM thermal self-responsive functionality in cementitious composites.
An implantable probe is provided herein. The implantable probe includes a plurality of wires configured for at least one of electromyography and electrical stimulation and a securing element formed at an end of the plurality of wires, wherein the plurality of wires are in a braided configuration and are configured to transmit multiple electrical signals in connection with a biological material. Also provided herein are a syringe based implantable probe system for positioning the implantable probe, and a method of making the implantable probe.
D03D 15/533 - Woven fabrics characterised by the material, structure or properties of the fibres, filaments, yarns, threads or other warp or weft elements used characterised by the properties of the yarns or threads antistaticWoven fabrics characterised by the material, structure or properties of the fibres, filaments, yarns, threads or other warp or weft elements used characterised by the properties of the yarns or threads electrically conductive
Provided are methods to convert - through a bottom-up approach – binary and ternary titanium carbides, nitrides, borides, phosphides, aluminides, and silicides into lepidocrocitic nanofilaments that in some cases self-assemble into 2D flakes by immersing them in a quaternary ammonium solution at moderate temperatures. The resulting flakes can be C-containing layers that are in turn comprised of nanofilaments in cross-section, some of which nanofilaments can be few microns long in some instances.
A method of detecting the length of an individual telomere is provided. In one embodiment, the method includes contacting genomic DNA with a guide RNA having a portion complementary to a telomere repeat sequence in the genomic DNA and with Cas9 nickase to produce a single-strand break in the genomic DNA at the telomere repeat sequence. The nicked DNA is contacted with a polymerase and fluorescently labeled nucleotide, wherein the fluorescently labeled nucleotide is incorporated into the nicked DNA at the telomere repeat sequence. The genomic DNA is contacted with a second nicking endonuclease which is specific for a sequence motif in the genomic DNA thereby producing a second nick in the genomic DNA at the motif sequence. The nicked DNA is contacted with a polymerase and second fluorescently labeled nucleotide of different color, wherein the second fluorescently labeled nucleotide is incorporated into the nicked DNA at the motif sequence location. The length of the telomere is detected by measuring the fluorescence of first fluorescently labeled nucleotide at the telomere repeat location, wherein the fluorescently labeled motif sequences are used as a barcode to identify the chromosome.
The present invention relates to innovative means of generating sequence-linked DNA fragments and subsequent uses of such linked DNA fragments for de novo haplotype-resolved whole genome mapping and massively parallel sequencing. In various embodiments described herein, the methods of the invention relate to methods of generating linked-paired end nucleic acid fragments sharing common linker nucleic acid sequences using a computationally-designed sgRNA library together with a nicking RNA-guided endonuclease, methods of analyzing the nucleotides sequences from the linked-paired-end sequenced fragments, and methods of de novo whole genome mapping. Thus, the methods of this invention allow establishing sequence contiguity across the whole genome, and achieving high-quality, low-cost de novo assembly of complex genomes.
The Trustees of the University of Pennsylvania (USA)
The Regents of the University of Colorado (USA)
The Board of Regents of the University of Oklahoma (USA)
Drexel University (USA)
Inventor
Lee, Daeyeon
Soroush, Masoud
Kaar, Joel
Papavassiliou, Dimitrios
Stebe, Kathleen J
Abstract
Systems, comprising: an aqueous medium, the aqueous medium having an amount of DNA disposed therein, the aqueous medium having one or more RNA polymerases disposed therein; and a non-aqueous medium. Methods, the methods comprising operating a system according to the present disclosure, so as to give rise to an RNA product disposed in the non-aqueous medium. Methods, comprising: with an RNA polymerase in an aqueous medium, effecting synthesis of an RNA product from template DNA, and selectively transferring the RNA product to a non-aqueous medium.
The present disclosure is directed to methods for scrubbing low levels of urea from aqueous solutions such as a dialysate from dialysis, and including blood and blood products, and devices capable of employing these methods.
B01J 20/02 - Solid sorbent compositions or filter aid compositionsSorbents for chromatographyProcesses for preparing, regenerating or reactivating thereof comprising inorganic material
A61M 1/16 - Dialysis systemsArtificial kidneysBlood oxygenators with membranes
B01D 15/08 - Selective adsorption, e.g. chromatography
B01J 20/28 - Solid sorbent compositions or filter aid compositionsSorbents for chromatographyProcesses for preparing, regenerating or reactivating thereof characterised by their form or physical properties
C02F 1/28 - Treatment of water, waste water, or sewage by sorption
78.
METHODS OF TREATING, AMELIORATING AND/OR PREVENTING WOUNDS
Described herein is method of treating, ameliorating and/or preventing a wound in a subject in need thereof. The method includes: collecting a first sample from the wound at a first timepoint and determining a first CCL1 (chemokine ligand 1) level in the first sample; administering to the subject a first treatment that promotes wound healing; collecting a second sample from the wound at a second timepoint after the first timepoint and determining a second CCL1 level in the second sample; and (a) if the second CCL1 level is higher than the first CCL1 level times a predetermined value, continuing the administration of the first treatment or discontinuing the first treatment, (b) if the second CCL1 level is equal to or lower than the CCL1 level times the predetermined value, administering to the subject a second treatment that promotes wound healing.
A61P 17/02 - Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
A61P 1/04 - Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
79.
SOLUTIONS FOR CONTINUOUS INFUSION OF A DRUG ADMINISTERED VIA DIALYSIS AND DOSING ALGORITHM THEREFOR
A method of preparing a solution for use during a dialysis, hemodialysis, or Continuous Renal Replacement Therapy (CRRT) treatment of a patient is provided. An antibiotic or other drug is added (48, 50, 52) to a solution and the concentration or dosing of the antiboitic or other drug within the solution is adjusted (72) as required based on a determiniation (64) of serum level of the antibiotic in a blood sample of a patient.
Provided are methods of stabilizing MXene compositions using polyanionic salts so as to reduce the oxidation of the MXenes. Also provided are stabilized MXene compositions.
A method for evaluating reading comprehension is provided. The method includes the steps of providing at least one printed passage of text; providing a test subject, the test subject wearing a device for measuring brain frontal lobe usage; requiring the test subject to read the printed passage; providing a question based on the printed passage for the test subject to answer; and determining whether the device measures brain frontal lobe usage. A system for performing the method is also provided.
G09B 7/02 - Electrically-operated teaching apparatus or devices working with questions and answers of the type wherein the student is expected to construct an answer to the question which is presented or wherein the machine gives an answer to the question presented by the student
A61B 5/00 - Measuring for diagnostic purposes Identification of persons
The present application is directed, in part, to compounds, and/or pharmaceutically acceptable salts or solvates thereof, and/or pharmaceutical compositions thereof, for modulating the activity of Sigma1 receptor. The present application is further directed, in part, to methods for treating and/or preventing cancer using compounds disclosed herein, and/or pharmaceutically acceptable salts or solvates thereof, and/or pharmaceutical compositions thereof.
A tunable shielding component, comprising: a first portion of MXene; a second portion of MXene; and a separator disposed between the first portion of MXene and the second portion of MXene, the separator having an electrolyte disposed therein. An electronic device, comprising a tunable shielding component according to the present disclosure. A method, comprising applying a potential to a tunable shielding component according to the present disclosure so as to effect a change in the EMI SE of the tunable shielding component.
B32B 23/04 - Layered products essentially comprising cellulosic plastic substances comprising such substance as the main or only constituent of a layer, next to another layer of a specific substance
B32B 27/06 - Layered products essentially comprising synthetic resin as the main or only constituent of a layer next to another layer of a specific substance
B32B 27/18 - Layered products essentially comprising synthetic resin characterised by the use of special additives
An anatomically fitted talar component for use in an ankle replacement system having a body including a talar surface having a portion contoured to approximately or exactly fit with a surface portion of a three dimensional rendering of bone of a talar dome; and a tibial surface configured for forming a joint with a second component of the ankle replacement system. A method of forming the talar component by: (i) obtaining image data of the talar dome, (ii) using the data to create a three-dimensional model of the talar dome, and (iii) forming a body having a talar surface that approximately or exactly fits with a portion of the surface of the three-dimensional model.
THETRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (USA)
DREXEL UNIVERSITY (USA)
Inventor
Diaz-Arrastia, Ramon
Izzetoglu, Kurtulus
Reddy, Pratusha
Le, My Duyen
Abstract
The disclosed subject matter provides a device and a method for inducing and sustaining hypercapnia of a subject. The device can include a tube, a face mask for breathing of the subject, a gas collection reservoir for collecting an expired gas from the subject, a valve chamber, a sensor for detecting a carbon dioxide level from the expired gas from the subject, and a controller configured to control a partition of the valve chamber for changing a gas composition in the valve chamber based on the readings of the sensor. The valve chamber can include a first opening, a second opening, and a third opening, wherein the first opening can be configured to allow an external air flowing into the valve chamber, and the expired gas flowing out from the valve chamber, wherein the second opening, coupled to the face mask through the tube, can be configured to allow a gas passage between the subject and the valve chamber, wherein the third opening, coupled to the gas collection reservoir though the tube, can be configured to allow a gas passage between the valve chamber and the gas collection reservoir.
Disclosed is a method for treating actinic keratosis of tissue of a patient, the method including contacting non-thermal, atmospheric pressure plasma over areas of the tissue having actinic keratosis for a time and at treatment conditions effective to give rise to an at least partial amelioration of the keratosis.
A method, comprising: combining at least a MXene, a solvent, and an electrochemically active material to form a slurry, the solvent consisting essentially of water, alcohol, or a combination of alcohol and water. An electrode, comprising: a structure comprising a MXene and an electrochemically active material, the structure optionally having a cross-sectional dimension of from about 1 to about 300 μm in thickness, preferably from about 10 to about 100 μm; and optionally a substrate on which the film is disposed. A device, the device comprising an electrode according to the present disclosure (for example, according to any one of Aspects 14-19). A method, comprising operating a device according to the present disclosure (for example, according to any one of Aspects 21-22).
H01M 4/1391 - Processes of manufacture of electrodes based on mixed oxides or hydroxides, or on mixtures of oxides or hydroxides, e.g. LiCoOx
H01M 4/1397 - Processes of manufacture of electrodes based on inorganic compounds other than oxides or hydroxides, e.g. sulfides, selenides, tellurides, halogenides or LiCoFy
88.
COMPOSITIONS FOR INHIBITING VIRAL ENTRY AND METHODS USING SAME
The present disclosure relates, in part, to a composition for promoting virolysis and/or inhibition of infection of a vims in a mammal, the composition comprising a lectin mutant. In certain embodiments, the lectin mutant comprises mutant cyanovirin N (CVN) and mutant Griffithsin (GRFT). The present disclosure further provides methods of treating, preventing, and/or ameliorating viral infection in a subject. In certain embodiments, the viral infection is caused by a vims selected from the group consisting of SARS-CoV-1, SARS-CoV-2, and HIV-I. The present disclosure further provides cyclic compounds useful for the treatment, prevention, and/or amelioration of HIV-I in a subject.--
A61K 47/60 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
C07K 7/60 - Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation occurring through the 4-amino group of 2,4-diamino-butanoic acid
THE TRUSTEES OF THE UNIVERSITY OFPENNSYLVANIA (USA)
DREXEL UNIVERSITY (USA)
Inventor
Brenner, Jacob, S.
Lingamoorthy, Anush, N.
Gordon, David
Donlon, Ethan, Comelius
Baston, Cameron
Lam, Khang
Abstract
A wearable device is provided for recognition and response to an overdose, such as an opioid overdose. The device includes an oximetry sensor for measuring peripheral oxygen saturation (SpO2) of a wearer of the wearable device and a motion sensor for determining whether the wearer of the wearable device is moving or motionless. The wearable device further includes an injector including a supply of an antidote and a needle for intramuscular delivery of the antidote to the wearer of the wearable device. The wearable device may also include a housing in which the oximetry sensor, the motion sensor, and the supply of the antidote is contained and in which the needle is initially contained in a retracted condition. The wearable device may further include a strap extending from the housing and sized to secure the housing on an upper arm of the wearer adjacent the shoulder of the wearer
A method for developing an antimicrobial includes coating a cyclodextrin-based metal-organic framework (CD-MOF-1) solution on a polypropylene fabric. The method further includes forming a MOF-coated fabric based on the CD-MOF-1 coating. The method further may load a benzalkonium chloride (BAC)-based surfactant on the MOF-coated fabric to develop the antimicrobial fabric.
A field-programmable analog array (FPAA) fabric includes a 6×6 matrix of configurable analog blocks (CABs). The implementation of programmable CABs eliminates the use of fixed analog subcircuits. A unique routing strategy is developed within the CAB units that supports both differential and single-ended mode circuit configurations. The bandwidth limitation due to the routing switches of each individual CAB unit is compensated for through the use of a switch-less routing network between CABs. Algorithms and methodologies facilitate rapid implementation of analog circuits on the FPAA. The proposed FPAA fabric provides high operating speeds as compared to existing FPAA topologies, while providing greater configuration in the CAB units as compared to switch-less FPAA. The FPAA core includes 498 programming switches and 14 global switchless interconnects, while occupying an area of 0.1 mm2 in a 65 nm CMOS process.
H03K 19/17704 - Logic circuits, i.e. having at least two inputs acting on one outputInverting circuits using specified components using elementary logic circuits as components arranged in matrix form the logic functions being realised by the interconnection of rows and columns
H03K 19/17736 - Structural details of routing resources
H04B 7/04 - Diversity systemsMulti-antenna systems, i.e. transmission or reception using multiple antennas using two or more spaced independent antennas
H01Q 19/10 - Combinations of primary active antenna elements and units with secondary devices, e.g. with quasi-optical devices, for giving the antenna a desired directional characteristic using reflecting surfaces
H04L 41/0813 - Configuration setting characterised by the conditions triggering a change of settings
H01Q 19/18 - Combinations of primary active antenna elements and units with secondary devices, e.g. with quasi-optical devices, for giving the antenna a desired directional characteristic using reflecting surfaces having two or more spaced reflecting surfaces
Pharmaceutical compositions comprising a RelA enzyme inhibitor and a bactericidal antibiotic, wherein said RelA enzyme inhibitor binds to the RelA enzyme in bacteria to reduce biofilm formation and to degrade biofilms that have been formed. The pharmaceutical compositions can be used to treat bacterial biofilm diseases.
A61K 31/341 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
A61K 31/43 - Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula , e.g. penicillins, penems
A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
A61K 31/7008 - Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine
C07D 231/12 - Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
22) and systems for carrying out the processes. Liquid water is contacted with an amount of a 1D and/or 2D carbon-doped nanofilament-based photocatalyst material composition and a hole scavenger chemical, optionally under an inert gas purge, at temperature of 100 ºC or less, generating gaseous molecular hydrogen by irradiating the liquid water, the hole scavenger chemical, and the photocatalyst for about 1 to 300 hours with at least one sun illumination (UV-Vis light (250–650 nm)).
C01B 3/04 - Production of hydrogen or of gaseous mixtures containing hydrogen by decomposition of inorganic compounds, e.g. ammonia
B01J 35/00 - Catalysts, in general, characterised by their form or physical properties
C25B 1/04 - Hydrogen or oxygen by electrolysis of water
B01J 23/89 - Catalysts comprising metals or metal oxides or hydroxides, not provided for in group of the iron group metals or copper combined with noble metals
A hydroponic growing system includes a base member, an upper tray removably inserted into the base member, and a lid portion removably attachable to the base member. The lid portion comprises a funnel extending from a top end of the lid toward a bottom end of the lid and a sidewall having a plurality of openings formed therein.
A superconducting solid-state circuit breaker (S3CB) may be used in direct current (DC) power system applications. The proposed protective S3CB has two main protective functions. First, it slows down a rising rate of fault currents by using superconductors. A new quench resistor accelerator is proposed to fasten superconductors' response time to solve the low inertia of DC power systems. In addition, a quench protection branch is used to protect the superconductors from localized hotspots during current limiting processes. Second, the proposed S3CB includes an ultrafast solid-state circuit breaker (SSCB) which isolates faulty sections or disconnect loads within microseconds.
H02H 3/087 - Emergency protective circuit arrangements for automatic disconnection directly responsive to an undesired change from normal electric working condition, with or without subsequent reconnection responsive to excess current for DC applications
H02H 3/20 - Emergency protective circuit arrangements for automatic disconnection directly responsive to an undesired change from normal electric working condition, with or without subsequent reconnection responsive to excess voltage
H02H 3/16 - Emergency protective circuit arrangements for automatic disconnection directly responsive to an undesired change from normal electric working condition, with or without subsequent reconnection responsive to fault current to earth, frame or mass
H02H 3/17 - Emergency protective circuit arrangements for automatic disconnection directly responsive to an undesired change from normal electric working condition, with or without subsequent reconnection responsive to fault current to earth, frame or mass by means of an auxiliary voltage injected into the installation to be protected
H02H 3/38 - Emergency protective circuit arrangements for automatic disconnection directly responsive to an undesired change from normal electric working condition, with or without subsequent reconnection responsive to both voltage and currentEmergency protective circuit arrangements for automatic disconnection directly responsive to an undesired change from normal electric working condition, with or without subsequent reconnection responsive to phase angle between voltage and current
H02H 9/02 - Emergency protective circuit arrangements for limiting excess current or voltage without disconnection responsive to excess current
H02H 9/04 - Emergency protective circuit arrangements for limiting excess current or voltage without disconnection responsive to excess voltage
97.
LIGHTWEIGHT AGGREGATES PRODUCED FROM WASTE-COAL COMBUSTION ASH
Manufacturing lightweight aggregate (LWA) by a sintering technique requires a delicate balance among three conditions: forming sufficient amount of molten liquid phase during sintering; reaching an appropriate viscosity for solid-liquid suspension; and emitting sufficient amount of gas that can be entrapped by the liquid phase to form pores. LWAs were made from low-calcium and high-calcium Waste Coal Combustion Ash (W-CCA) including fly ash and bottom ash. A mass fraction of at least 40% liquid phase for fly ash and 50% for bottom ash is required for a successful entrapment of emitted gaseous phases during sintering. Larger pores were observed in the microstructure of LWA samples made using high-calcium W-CCA in comparison to low-calcium W-CCA. This result was mainly attributed to the high-calcium samples forming liquid phases with lower viscosity values and emitting higher amounts of gaseous phase during sintering than did the low-calcium samples. The gaseous phase was generated by hematite reduction and anhydrite decomposition.
Cancers develop specific metabolic adaptations such as the opportunistic utilization of acetate as an alternative carbon source and the generation of acetyl-CoA mediated by ACSS-2, which is upregulated in response to nutrient and hypoxic stress. This pathway can fuel various processes involving acetyl-CoA, including de novo fatty acid synthesis and protein acetylation. Provided herein are methods of treating a cancerous disease in a subject using compounds that inhibit ACSS-2.
A device and method of thixotropic mixing and 3D printing of alloys is provided. The method includes the steps of locating a thixotropic mixer having a discharge nozzle above a substrate; adding a molten alloy to the mixer; locating the nozzle between about 1 mm and about 20 mm from the substrate; and extruding the alloy from the nozzle onto the substrate.
A simulation-based optimization framework determines the sizing of components of an analog circuit to meet target design specifications while also satisfying the robustness specifications set by the designer. The robustness is guaranteed by setting a limit on the standard deviations of the variations in the performance parameters of a circuit across all process and temperature corners of interest Classifier chains are used that, in addition to modeling the relationship between inputs and outputs, learn the relationships among output labels. Additional design knowledge is inferred from the optimal ordering of the classifier chain.
G06F 30/367 - Design verification, e.g. using simulation, simulation program with integrated circuit emphasis [SPICE], direct methods or relaxation methods
